Imipramine Crescent Pharma

Imipramine, the active ingredient in Imipramine Crescent Pharma, is a tricyclic antidepressant presented as an oral dosage form for oral use. It treats major depressive disorder and related conditions in adult patients.

GNH USA supplies Imipramine Crescent Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Imipramine is a tricyclic antidepressant that acts on mood‑regulating pathways and is prescribed for several recognized conditions. - Major depressive disorder: alleviates depressive symptoms and improves mood in adults. - Panic disorder: reduces frequency and severity of panic attacks. - Nocturnal enuresis (children): decreases nighttime urinary leakage by modulating bladder control.

Imipramine may cause a range of adverse reactions, some of which are frequent and others that are uncommon but serious.

Common Side Effects: - Dry mouth: reduced salivary flow causing discomfort. - Drowsiness: increased sedation, especially at treatment initiation. - Constipation: slowed gastrointestinal motility. - Blurred vision: temporary visual disturbances.

Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm that may require monitoring. - Seizures: heightened risk in predisposed individuals. - Severe hypotension: sudden drop in blood pressure, especially when standing.

Before initiating therapy, clinicians should evaluate specific safety considerations. - Cardiac monitoring: assess ECG and heart rhythm, particularly in patients with pre‑existing heart disease. - Suicidal ideation: monitor mood changes, especially during early treatment. - Elderly patients: start with lower doses to reduce anticholinergic burden. - Discontinuation: avoid abrupt cessation to prevent withdrawal symptoms. - Hepatic impairment: adjust dose if liver function is compromised. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Imipramine can interact with several drug classes, influencing efficacy and safety.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of severe serotonin syndrome. - Selective serotonin reuptake inhibitors (SSRIs): additive serotonergic effects. - Central nervous system depressants: enhanced sedation and respiratory depression.

Moderate Interactions (Monitor Closely):\n- Anticholinergic agents: increased anticholinergic side‑effects. - Diuretics: heightened orthostatic hypotension. - CYP2D6 inhibitors: elevated imipramine plasma concentrations.